Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trial

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJeff P. SharmanLLLuca LaurentiLMLuis Felipe Casado Montero

Discussion

Loading...

Member takes

Overview

Phase III trial shows improved immune reconstitution in chronic lymphocytic leukemia with undetectable MRD, suggesting venetoclax-obinutuzumab may enhance treatment outcomes.

Key Points

  • Sustained CLL cell depletion was achieved in patients with undetectable minimal residual disease.
  • Overall, 81.3% of patients receiving venetoclax-obinutuzumab reached undetectable MRD at month 15, versus 54.7% with FCR/BR.
  • Analysis used immune profiling throughout treatment and follow-up, assessing lymphocyte subsets and immunoglobulin levels.
  • Findings highlight effective immune recovery with venetoclax-obinutuzumab, alongside maintained deep remissions.

Cite This Study

Sharman et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d74fhttps://doi.org/10.1182/blood-2025-682
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long term follow-up and results of retreatement after obinutuzumab-venetoclax in first-line CLL patients with coexisting conditions2025
  2. 2Venetoclax-based therapy remodels T-cell and NK-cell immunity in patients with chronic lymphocytic leukemia2025
  3. 3Venetoclax-obinutuzumab in frontline and R/R CLL: Outcomes compared to age- and sex-matched general population2025
  4. 4Immune reconstitution after venetoclax-based treatments in CLL2025
  5. 5Efficacy of fixed-duration venetoclax-based regimens as first-line in chronic lymphocytic leukemia: A systematic review and meta-analysis of clinical trials2025